Business

March 21, 2022 After Hours Revenue Report: NKE, TME, ORIC, TELA, DRIO, CXDO, SSKN, KERN


JThe following companies are expected to report after-hours earnings on 03/21/2022. See our results calendar for a full list of expected results releases.

Nike, Inc. (NKE) reports for the quarter ending Feb. 28, 2022. The retail footwear and apparel company’s consensus earnings per share forecast from the 13 analysts who track the stock is $0.73. This value represents a decrease of 18.89% compared to the same quarter last year. Over the past year, NKE has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat consensus by 31.75%. Zacks Investment Research reports that the 2022 price-to-earnings ratio for NKE is 35.96 versus an industry ratio of 16.30, implying that they will have higher earnings growth than their competitors in the same industry.

Tencent Music Entertainment Group (TME) releases a report for the quarter ending December 31, 2021. The internet content company’s consensus earnings per share forecast from the 2 analysts who track the stock is $0.06. This value represents a decrease of 45.45% compared to the same quarter last year. TME missed consensus Q1 calendar 2021 earnings per share by -10%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for TME is 15.81 versus an industry ratio of 19.10.

Oric Pharmaceuticals, Inc. (ORIC) reports for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 4 analysts who track the stock is -$0.61. This value represents an increase of 27.38% compared to the same quarter last year. The “days to cover” for this stock exceeds 15 days. Zacks Investment Research reports that the 2021 price-to-earnings ratio for ORIC is -3.21 versus an industry ratio of -17.30, implying they will have higher earnings growth than their competitors in the same sector.

TELA Bio, Inc. (TELA) releases its report for the quarter ending Dec. 31, 2021. The consensus earnings-per-share forecast for the biomedical company (gene) from the top analyst tracking the stock is -$0.54. This value represents a no change for the same quarter last year. Zacks Investment Research reports that the 2021 price-to-earnings ratio for TELA is -5.56 versus an industry ratio of -17.30, implying that they will have higher earnings growth than their competitors in the same industry.

DarioHealth Corp. (DRIO) reports for the quarter ending Dec. 31, 2021. The medical devices company’s consensus earnings-per-share forecast from the 3 analysts who track the stock is -$1.13. This value represents a decrease of 6.60% compared to the same quarter last year. Zacks Investment Research reports that the 2021 price-to-earnings ratio for DRIO is -1.54 versus an industry ratio of -11.40, implying that they will have higher earnings growth than their competitors in the same industry.

Crexendo, Inc. (CXDO) reports for the quarter ending Dec. 31, 2021. The internet services company’s consensus earnings-per-share forecast from the top analyst tracking the stock is $0.02. This value represents a decrease of 94.59% compared to the same quarter last year. Zacks Investment Research reports that the 2021 price-to-earnings ratio for CXDO is 51.38 versus an industry ratio of -7.10, implying that they will have higher earnings growth than their competitors in the same industry.

Strata Skin Sciences, Inc. (SSKN) reports for the quarter ending Dec. 31, 2021. The medical information systems company’s consensus earnings per share forecast from the top analyst tracking the stock is -$0.03. This value represents a decrease of 200.00% compared to the same quarter last year. SSKN missed consensus earnings per share in the 1st calendar quarter of 2021 by -133.33%. Zacks Investment Research reports that the 2021 P/E ratio for SSKN is -11.00 versus an industry ratio of -1.60.

Akerna Corp. (KERN) reports for the quarter ending Dec. 31, 2021. The medical products company’s consensus earnings-per-share forecast from the 2 analysts who track the stock is -$0.14. This value represents an increase of 51.72% compared to the same quarter last year. KERN missed consensus Q2 calendar 2021 earnings per share by -13.33%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for KERN is -1.68 versus an industry ratio of 6.80.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


nasdaq

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.

Eleon

"Writer. Coffee practitioner. Twitter specialist. Food trailblazer. Subtly charming analyst. Troublemaker. Unable to type with boxing gloves on."
Back to top button